

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86614

Masakazu SATO, *et al.*

National Stage Application of  
PCT/JP03/11603  
-filed September 11, 2003

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: March 11, 2005

Examiner: Not Yet Assigned

For: N-HYDROXYFORMAMIDINE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

European Patent No. 1 291 343A is the corresponding application to WO 01/96309A1.

European Patent No. 1 226 819A1 is listed on the International Search Report, a copy of which is submitted herewith.

0/527716

Information Disclosure Statement  
National Stage Application of  
PCT/JP03/11603  
-filed September 11, 2003

Q86614

DT09 Rec'd PCT/PTO 11 MAR 2005


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

  
Susan J. Mack  
Registration No. 30,951

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 11, 2005

Substitute for Form 1449 A & B/PTO  <b><u>INFORMATION DISCLOSURE</u></b> <b><u>STATEMENT BY APPLICANT</u></b>  <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number Confirmation Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	National Stage Application of PCT/JP0312603 - filed September 11, 2003 Not Yet Assigned March 11, 2005 Masakazu SATO Not Yet Assigned Q86614
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		EP	1 291 343	A1	03-12-2003	Taisho Pharmaceutical Co., Ltd.	
		WO	01/68610	A1	09-20-2001	Taisho Pharmaceutical Co., Ltd.	
		JP	2001-354656	A	12-25-2001	Taisho Pharmaceutical Co., Ltd.	Abstract
		JP	2001-354658	A	12-25-2001	Taisho Pharmaceutical Co., Ltd.	Abstract
		EP	1 226 819	A1	07-31-2002	Taisho Pharmaceutical Co., Ltd.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		D.R. HARDER, <i>et al.</i> "Role of Cytochrome P-450 Enzymes and Metabolites of Arachidonic Acis in the Control of Vascular Tone" <i>J. Vasc Res</i> 1995; 32:79-92	
		JOHN C. MCGIFF, <i>et al.</i> :20-HETE and the kidney: resolution of old problems and new beginnings" <i>Am. J. Physiol.</i> 1999, Vol. 27, pp. R607-R623	
		RICHARD J. ROMAN "P-450 Metabolites of Aarchidonic Acid in the Control of Cardiovascular Function" <i>Physiol Rev</i> 82: 131-185, 2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.